ArticleJournal for immunotherapy of cancer2022

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10

George R Blumenschein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.